Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet reported Q3 net sales of $2.063 billion, up 3.1% reported and 3.7% in constant currency, and raised full-year organic constant-currency growth guidance to 3.0%-3.5% from 2.25%-3.25%; adjusted EPS guidance increased to $8.50-$8.60. Hip and S.E.T. sales grew 7.0% and 7.1% in constant currency, respectively, while knees declined 2.6% amid China headwinds and the U.S. sales-force transition; adjusted EPS was flat at $1.90 and operating margin fell 140 basis points to 25.1%. Management expects to submit Monogram’s FDA 510(k) application shortly and now anticipates a potential launch in the first half of 2027, subject to approval. Free cash flow rose 34% to $372 million in the quarter, and the company remains on track for approximately $1 billion of 2026 share repurchases.

Analysis

The bullish case is a mix shift, not yet proven operating leverage. Faster-growing S.E.T. and technology can reduce the earnings sensitivity to knees over time, but robotics growth is not equivalent to high-margin recurring profit: specialist hiring, training, installations and surgeon conversion may absorb revenue gains before utilization scales. The quarter’s margin pressure and nearly flat adjusted EPS make that timing the key debate. Buybacks support per-share results, but also compete with the stated opportunity to deploy capital into higher-growth acquisitions.

The market may be over-crediting the 2027 bridge. China comparisons become easier, but distributor normalization is not the same as recovered demand; Monogram remains contingent on FDA clearance, launch execution and adoption. The final, highest-risk phase of the U.S. sales-force change could delay knee recovery even as other franchises grow. ASC migration is a two-sided lever: portable robotics could improve account access, while buyers’ focus on procedure economics may sustain pricing pressure.

Near term, guidance raises support sentiment, but there is limited evidence here of EPS acceleration. Over 1–3 months, watch knee trends, sales-force disruption and margin conversion. Over 6–18 months, Monogram clearance/adoption and commercial productivity matter more than launch timing alone. Verify reported sales against the earnings release before changing models: the supplied takeaways and transcript contain inconsistent quarterly sales figures.

Key Decisions for Investors

• Avoid chasing the earnings reaction. Consider a staged, modest long in ZBH only if the price action does not imply a rapid Monogram-driven earnings ramp; treat the thesis as portfolio diversification plus execution optionality, not a near-term margin turnaround.
• Use knee performance and margins as the risk controls: revisit or reduce the position if U.S. knees fail to stabilize as the sales-force transition progresses, or if operating-margin pressure worsens without corresponding growth gains. No price-based stop is appropriate without current market data.
• Over the next 1–3 months, monitor quarterly knee sales, commercial-transition costs and cash conversion. For 2027 estimates, require evidence of FDA clearance and surgeon adoption before assigning material Monogram revenue; a filing or demonstration alone is not a catalyst for booked earnings.